IPTRK3: a peptide targeting to TrkA for cancer pain therapy
Why IPTRK3? Many patients with cancer pain still cannot obtain sufficient pain relief with available drugs. New analgesic drugs for cancer pain treatment is urgently needed to develop. Develop a new agent suppressing both cancer pain and tumor proliferation!
-IPTRK3 has a direct inhibitory effect on TrkA tyrosine kinase activity.
-IPTRK3 suppresses both nociceptive and neuropathic pain in rodents.
-IPTRK3 suppresses proliferation of malignant cells in cell culture study.
- Uses & Applications
- R&D of new drugs
- Application/Publication No.
- Patent Filed
If you have any questions or would like to apply for a license, we recommend that you do so promptly. You can contact us by e-mail by clicking on the "Contact Us" button at the top of the page.